Review of antimicrobial peptides with anti‐<i>Helicobacter pylori</i> activity

Neshani, Alireza; Zare, Hosna; Eidgahi, Mohammad Reza Akbari; Chichaklu, Amin Hooshyar; Movaqar, Aref; Ghazvini, Kiarash

doi:10.1111/hel.12555

Cited by 64 publications

(39 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Following the development of antibiotic-resistant H. pylori strains, evaluation of AMPs has started for the treatment of this infection. Epinecidin-1 is one of the most potent AMPs which have been introduced so far [5]. This peptide can inhibit the growth of sensitive and antibiotic-resistant H. pylori strains with the MIC of 8–12 μg/ml.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities

Neshani

Zare

Eidgahi

et al. 2019

BMC Pharmacol Toxicol

Self Cite

View full text Add to dashboard Cite

Background Antibiotic-resistant pathogens are an emerging threat in this century. Epinecidin-1 is a multi-functional Antimicrobial Peptide (AMP) produced by Orange-spotted grouper ( Epinephelus coioides ) has been shown to have extensive potentials as an alternative for current antibiotics. Due to the huge costs for the study and the production of a new drug, if an antimicrobial peptide has other beneficial functions in addition to antimicrobial activities, it would be preferred. Methods In this study, properties and applications of Epinecidin-1 were investigated and addressed comprehensively. To achieve this, the Google Scholar search engine and three databases of PubMed, Scopus, and Web of Science were used. Results Epinecidin-1 is a cationic AMP with an alpha-helical structure. Seven functional usages of this peptide have been reported in the literature including antibacterial, antifungal, antiviral, antiprotozoal, anticancer, immunomodulatory, and wound healing properties. Moreover, this peptide has high potential to be used as an active ingredient in cleaning solutions as well as application in vaccine production. Conclusion Due to significant antimicrobial activities tested on bacteria such as Staphylococcus aureus and Helicobacter pylori and also wound healing properties, Epi-1 has high potential to be considered as an important candidate for the production of new drugs and treatment of various infections including diabetic foot ulcer and peptic ulcer. Moreover, adjuvant-like properties of Epi-1 make it a suitable candidate for the studies related to an adjuvant. Other attractive properties such as anticancer effects have also been reported for this peptide which encourages further studies on this peptide.

show abstract

Section: Resultsmentioning

confidence: 99%

“…One of the main advantages of these AMPs is their good antimicrobial effect against multidrug-resistant pathogens. Although these peptides are usually known by their antimicrobial effect, they have some other properties including anti-cancer, immunomodulatory, wound healing, and antioxidant effects [3–5].…”

Section: Introductionmentioning

confidence: 99%

Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities

Neshani

Zare

Eidgahi

et al. 2019

BMC Pharmacol Toxicol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Furthermore, changing properties of membrane components to avoid interaction of AMPs could lead to the consequence of failing to colonize in the highly acidic stomach environment. Recently, more than 22 AMPs with positively charge and mostly having alpha-helical structure were demonstrated to show anti- H. pylori properties in vitro [ 91 ]. However, to be success in vivo , the essential requirements of AMPs applications includes having long duration staying in stomach while being relatively stable and remaining their antimicrobial potency in gastric environment.…”

Section: Applications Of Amps In Some Infectious Diseasesmentioning

confidence: 99%

Antimicrobial peptides – Advances in development of therapeutic applications

2020

View full text Add to dashboard Cite

The severe infection is becoming a significant health problem which threaten the lives of patients and the safety and economy of society. In the way of finding new strategy, antimicrobial peptides (AMPs) - an important part of host defense family, emerged with tremendous potential. Up to date, huge numbers of AMPs has been investigated from both natural and synthetic sources showing not only the ability to kill microbial pathogens but also propose other benefits such as wound healing, anti-tumor, immune modulation. In this review, we describe the involvements of AMPs in biological systems and discuss the opportunity in developing AMPs for clinical applications. In the detail, their properties in antibacterial activity is followed by their application in some infection diseases and cancer. The key discussions are the approaches to improve biological activities of AMPs either by modifying chemical structure or incorporating into delivery systems. The new applications and perspectives for the future of AMPs would open the new era of their development.

show abstract

“…The 3 peptides with the strongest anti-H. pylori activity were pexiganan, tilapia piscidin 4 (TP4), and PGLa-AM1. These 5-kDa peptides with α-helical structures are cationic and have high positive charge and isoelectric point (Neshani et al 2019). Most anti-H. pylori peptides have the activity against some antibiotic-resistant strains.…”

Section: Antimicrobial Peptides In the Treatment Of H Pylorimentioning

confidence: 99%

Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets

Roszczenko-Jasińska

Wojtyś

Jagusztyn-Krynicka

2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Helicobacter pylori, a member of Epsilonproteobacteria, is a Gram-negative microaerophilic bacterium that colonizes gastric mucosa of about 50% of the human population. Although most infections caused by H. pylori are asymptomatic, the microorganism is strongly associated with serious diseases of the upper gastrointestinal tract such as chronic gastritis, peptic ulcer, duodenal ulcer, and gastric cancer, and it is classified as a group I carcinogen. The prevalence of H. pylori infections varies worldwide. The H. pylori genotype, host gene polymorphisms, and environmental factors determine the type of induced disease. Currently, the most common therapy to treat H. pylori is the first line clarithromycin–based triple therapy or a quadruple therapy replacing clarithromycin with new antibiotics. Despite the enormous recent effort to introduce new therapeutic regimens to combat this pathogen, treatment for H. pylori still fails in more than 20% of patients, mainly due to the increased prevalence of antibiotic resistant strains. In this review we present recent progress aimed at designing new anti-H. pylori strategies to combat this pathogen. Some novel therapeutic regimens will potentially be used as an extra constituent of antibiotic therapy, and others may replace current antibiotic treatments. Key points • Attempts to improve eradication rate of H. pylori infection. • Searching for new drug targets in anti-Helicobacter therapies.

show abstract

Review of antimicrobial peptides with anti‐Helicobacter pylori activity

Cited by 64 publications

References 81 publications

Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities

Epinecidin-1, a highly potent marine antimicrobial peptide with anticancer and immunomodulatory activities

Antimicrobial peptides – Advances in development of therapeutic applications

Helicobacter pylori treatment in the post-antibiotics era—searching for new drug targets

Contact Info

Product

Resources

About